GIP, or glucose-dependent insulinotropic polypeptide, is released after nutrient intake and plays an important role in incretin biology. Like GLP-1, it is involved in post-prandial signaling, but the research emphasis is different. GIP is primarily discussed in relation to glucose-stimulated insulin signaling and downstream nutrient-sensing responses at the receptor level.

Rather than treating GIP as interchangeable with GLP-1, it is more accurate to describe it as contributing a distinct part of the metabolic signal. GIP is more strongly associated with nutrient sensing and insulin-response pathways, while GLP-1 is more involved in gastric emptying rate and post-prandial glucose dynamics. This distinction is why researchers have studied combining them as a dual-receptor approach.

GIP can be described as part of the post-prandial signaling system — shaping insulin secretion and metabolic coordination at the receptor level.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, designed to engage both incretin pathways simultaneously. This matters because GIP and GLP-1 are related but distinct signals — each contributing differently to post-prandial glucose handling, insulin-response signaling, and metabolic regulation.

GLP-1 receptor activation is associated with slowed gastric emptying and glucose-dependent insulin secretion. GIP receptor activation contributes nutrient-response signaling and additional insulin-related effects. When both are activated together, the research question is whether dual-receptor activation produces a distinct metabolic profile compared to single-pathway agonism.

The dual-receptor framework is what distinguishes tirzepatide mechanistically from earlier single-receptor GLP-1 compounds. Research interest centres on the interaction between the two incretin pathways and what that means for metabolic signaling at the receptor level.

Glutathione is a tripeptide molecule with a central role in intracellular redox balance. Unlike GLP-1, GIP, or glucagon, it is not part of the incretin hormone family. Its primary research interest lies in how cells manage reactive oxygen species, support detoxification pathways, and maintain cellular integrity under oxidative stress conditions.

It is often described as the body's most abundant endogenous antioxidant, and research interest spans oxidative stress modulation, cellular resilience, and the role of redox signaling in broader metabolic and inflammatory contexts.

Glutathione is distinct from metabolic peptide signaling compounds in that it operates at the level of cellular chemistry rather than receptor-mediated hormone signaling. This places it in a separate category within peptide and antioxidant research.

Retatrutide is a triple agonist designed to act on GLP-1, GIP, and glucagon receptors simultaneously. The first two pathways are already studied in incretin biology, while glucagon receptor activity adds a third layer. Glucagon signaling is associated with hepatic glucose production and energy substrate regulation, making it mechanistically distinct from the incretin pathways.

The research interest in retatrutide centres on how three receptor targets interact when activated by a single molecule. GLP-1 receptor activity contributes to post-prandial glucose regulation and gastric emptying; GIP receptor activity contributes nutrient-response and insulin-related signaling; glucagon receptor activity introduces additional metabolic effects through a different downstream pathway.

Retatrutide represents part of the broader research direction toward multi-pathway receptor agonism — studying how combined signalling across several related receptors differs from single or dual-receptor approaches.

GLP-1 receptor agonists engage a signaling pathway that extends across multiple organ systems. Research interest covers their effects on gastric emptying rate, glucose-dependent insulin secretion, glucagon suppression, and the downstream signaling that links gut hormone activity to broader metabolic regulation.

Rather than acting through a single mechanism, GLP-1 receptor activation produces a chain of metabolic responses — altering nutrient absorption rate and pancreatic glucose-response signaling. Research in this area examines each of these steps individually as well as their combined effects.

This multi-mechanism profile is why GLP-1 receptor agonists continue to attract significant research interest across metabolic biology, incretin physiology, and related fields.

GLP-1 receptor signaling is primarily studied in the context of metabolic and incretin biology, but research interest has expanded into inflammatory pathways. This is partly because metabolic dysfunction and chronic low-grade inflammation are frequently observed together, prompting investigation into whether GLP-1 receptor activity has relevant effects at the level of inflammatory signaling.

Research in this area examines GLP-1 receptor expression in immune-relevant tissues, potential effects on pro-inflammatory cytokine signaling, and interactions with oxidative stress pathways. Neuroinflammation has also become a growing area of interest given the presence of GLP-1 receptors in the central nervous system.

This line of research represents an expansion of GLP-1 biology beyond its classical incretin role, with ongoing study into how receptor activation may intersect with inflammatory and stress-response mechanisms.

GLP-1 receptors are expressed not only in peripheral metabolic tissues but also in regions of the central nervous system involved in reward processing and dopaminergic signaling. This has prompted research into how GLP-1 receptor activation may influence CNS pathway activity beyond its classical incretin role.

Research in this area examines GLP-1 receptor distribution in the brain, interactions with mesolimbic dopamine pathways, and potential effects on neuroinflammatory signaling. The overlap between metabolic hormone systems and CNS reward circuitry is an active area of study in neuropharmacology and receptor biology.

This represents a distinct and emerging line of GLP-1 research, separate from its metabolic and incretin applications, focused on receptor-level interactions within the central nervous system.

Semaglutide is a GLP-1 receptor agonist that has attracted significant research interest for its effects on incretin signaling, gastric emptying, and post-prandial glucose dynamics. It is one of the most studied single-pathway GLP-1 compounds in metabolic biology.

Irish Peptide Research supplies semaglutide as a research compound in Ireland, available for in vitro and laboratory use. Research applications include GLP-1 receptor binding studies, incretin pathway modelling, and metabolic signaling research.

All products are strictly for research use only and are not intended for human or animal consumption.

Tirzepatide engages both the GIP and GLP-1 receptor pathways simultaneously, producing a combined incretin signal that differs mechanistically from single-pathway agonists. Research interest centres on how dual-receptor activation affects metabolic signaling compared to individual pathway stimulation.

Irish Peptide Research supplies tirzepatide as a research compound in Ireland, supporting studies in incretin biology, dual-receptor pharmacology, and metabolic pathway research.

All products are strictly for research use only and are not intended for human or animal consumption.

Retatrutide adds glucagon receptor activity to the dual GIP/GLP-1 framework, creating a three-receptor compound studied for its broader metabolic signaling profile. Glucagon receptor activation introduces effects on hepatic glucose production and energy substrate regulation that are distinct from incretin pathway signaling alone.

Irish Peptide Research supplies retatrutide as a research compound in Ireland, supporting studies in triple-receptor agonism, metabolic pathway interactions, and incretin biology.

All products are strictly for research use only and are not intended for human or animal consumption.

BPC-157 (Body Protection Compound 157) is a partial sequence derived from a protein found in gastric juice. Research interest centres on its effects in tissue repair models, including tendon, muscle, and gastrointestinal tissue, as well as its interactions with angiogenic and nitric oxide signaling pathways.

Irish Peptide Research supplies BPC-157 as a research compound in Ireland, available for in vitro and laboratory research across a range of tissue and signaling models.

All products are strictly for research use only and are not intended for human or animal consumption.

TB-500 is based on the active region of thymosin beta-4, a naturally occurring peptide involved in actin sequestration and cell motility. Research applications include studies on cell migration, wound healing signaling pathways, and tissue repair models involving muscle, tendon, and cardiac tissue.

Irish Peptide Research supplies TB-500 as a research compound in Ireland, supporting preclinical studies in tissue biology and repair signaling.

All products are strictly for research use only and are not intended for human or animal consumption.

BPC-157 and TB-500 are mechanistically distinct peptides operating through different signaling pathways — BPC-157 through angiogenic and gastrointestinal signaling, TB-500 through actin regulation and cell migration. Research interest in combining them stems from the hypothesis that their distinct mechanisms may produce complementary effects in tissue repair models.

Irish Peptide Research supplies the BPC-157 and TB-500 combination as a research preparation in Ireland, alongside each compound individually.

All products are strictly for research use only and are not intended for human or animal consumption.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide with well-documented research interest in wound healing, skin biology, and gene expression modulation. Studies have examined its effects on collagen and glycosaminoglycan synthesis, antioxidant enzyme activity, and cellular repair signaling.

Irish Peptide Research supplies GHK-Cu as a research compound in Ireland, supporting studies in skin biology, repair signaling, and copper-peptide chemistry.

All products are strictly for research use only and are not intended for human or animal consumption.

HGH Fragment 176-191 is derived from amino acids 176 to 191 of the human growth hormone sequence. Research interest focuses on its interaction with fat cell receptors and lipolytic signaling pathways, distinct from the broader growth-promoting effects associated with full-length growth hormone.

Irish Peptide Research supplies HGH Fragment 176-191 as a research compound in Ireland, available for in vitro studies in lipolysis signaling, adipocyte biology, and growth hormone fragment pharmacology.

All products are strictly for research use only and are not intended for human or animal consumption.

Semaglutide is a GLP-1 receptor agonist studied extensively in metabolic research. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, represent further developments in incretin-based research compound availability.

Irish Peptide Research supplies semaglutide, tirzepatide, and retatrutide as research compounds in Ireland, supporting in vitro and laboratory research into these receptor pathways. All products are strictly for research use only and are not intended for human or animal consumption.

BPC-157, TB-500, GHK-Cu, and HGH Fragment 176-191 are peptide research compounds studied across tissue repair, cellular signaling, and metabolic research applications. Access to research-grade material within Ireland has historically been limited.

Irish Peptide Research supplies these compounds in Ireland for in vitro and laboratory research. All products are strictly for research use only and are not intended for human or animal consumption.

Retatrutide is informally known as Triple G or Triple-G in research circles, referring to its activity across three receptor pathways: GLP-1, GIP, and glucagon. This triple-receptor mechanism distinguishes it from earlier single and dual-receptor compounds such as semaglutide and tirzepatide.

Irish Peptide Research supplies Triple G (retatrutide) as a research compound in Ireland for in vitro and laboratory research use.

All products are strictly for research use only and are not intended for human or animal consumption.